Finch Therapeutics: We Will Get A Healthy Premium
2026-05-04
·
via All Articles on Seeking Alpha
Summary
- Finch shares declined from $13.49 at the end of 2025 to $9.64 at the end of the first quarter.
- Finch won a jury trial in August 2024 against Ferring Pharmaceuticals, with the jury finding that Ferring infringed on three of Finch's patents.
- Finch decided to move forward with a strategic Chapter 11 filing in order to eliminate the lease obligation and organize an outright sale of the company.
- The sale involves a litigation claim, 160 issued patents, an additional potential case of infringement involving a global corporation, and the corporate shell.
- Arquitos Capital believes that this process will maximize the value of Finch for shareholders and will monetize the assets more effectively than if Finch remained a publicly traded company.
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。
